Neovacs S.A Vállalati érték
Mi az Neovacs S.A Vállalati érték?
A Vállalati érték az Neovacs S.A. - -$31.13
Mi a Vállalati érték meghatározása?
A vállalati érték a vállalat teljes piaci értékének mértéke. A piaci kapitalizáció az adósság, a kisebbségi részesedés és a preferált részvények összege, a pénzeszközök és pénzeszköz-egyenértékek összege mínusz.
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
Vállalati érték a Health Care szektor a EURONEXT-on cégekben a Neovacs S.A -hoz képest
Mit csinál Neovacs S.A?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
vállalati érték -hoz hasonló cégek Neovacs S.A
- TDb Split nak Vállalati érték -$31.63 van
- Xinyuan Property Management Service (Cayman) nak Vállalati érték -$31.48 van
- Playmates Toys nak Vállalati érték -$31.42 van
- Capital VC nak Vállalati érték -$31.41 van
- Forgame nak Vállalati érték -$31.29 van
- Ellex Medical Lasers nak Vállalati érték -$31.28 van
- Neovacs S.A nak Vállalati érték -$31.13 van
- Ayala Pharmaceuticals nak Vállalati érték -$31.07 van
- Gracell Biotechnologies nak Vállalati érték -$31.05 van
- Graybug Vision nak Vállalati érték -$31.03 van
- Ourgame International nak Vállalati érték -$30.97 van
- Agora nak Vállalati érték -$30.92 van
- Canopy Rivers nak Vállalati érték -$30.42 van